Docusign Stock News

NEW YORK, Feb. 15, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of DocuSign, Inc. (NASDAQ: DOCU) between June 4, 2020 and December 2, 2021, both dates inclusive (the "Class Period"), of the important February 22, 2022…

Anyone who had to get documents signed early in the pandemic knows how harrowing and dangerous the situation was. Nobody wanted to meet face-to-face, but we still had to conduct business. Today, in an effort to simplify online document signing, Zoom and DocuSign announced a new integration that lets you review and sign a document […]

Anyone who had to get documents signed early in the pandemic knows how harrowing and dangerous the situation was. Nobody wanted to meet face-to-face, but we still had to conduct business. Today, in an effort to simplify online document signing, Zoom and DocuSign announced a new integration that lets you review and sign a document […]

7-Day Deadline Reminder: The Schall Law Firm Encourages Investors in DocuSign, Inc. with Losses of $250,000 to Contact the Firm

Anyone who had to get documents signed early in the pandemic knows how harrowing and dangerous the situation was. Nobody wanted to meet face-to-face, but we still had to conduct business.

NEW YORK, Feb. 13, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reata Pharmaceuticals, Inc. (NASDAQ: RETA ), Desktop Metal, Inc. (NYSE: DM ), DocuSign, Inc. (NASDAQ: DOCU ), and Arrival SA (NASDAQ: ARVL ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Reata Pharmaceuticals, Inc. (NASDAQ: RETA ) Class Period: November 14, 2016 December 8, 2021 Lead Plaintiff Deadline: February 18, 2022 The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company''s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the FDA had raised concerns regarding the validity of the clinical study designed to measure the efficacy and safety of bardoxolone for the treatment of chronic kidney disease caused by Alport syndrome; (2) that, as a result, there was a material risk that Reata''s NDA would not be approved; and (3) that, as a result of the foregoing, Defendants'' positive statements about the Company''s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

DocuSign Inc. (NASDAQ:DOCU)s traded shares stood at 0.66 million during the latest session, with the companys beta value hitting 0.92. At the last check today, the stocks price was $126.81, to imply a decrease of -0.32% or -$0.41 in intraday trading. The DOCU shares 52-week high remains $314.76, putting it -148.21% down since that peak After The Stock Rose 11.36% Over The Week, Is DocuSign Inc. (NASDAQ: DOCU) Still A Buy? Read More »

DOCU is well positioned to capitalize on the e-signature boom. Continues to enhance its solution to cater secure and automated agreements.

DocuSign Stock: Why I'll Pass For Now

NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of DocuSign, Inc. (NASDAQ: DOCU) between March 27, 2020 and December 2, 2021, both dates inclusive (the Class Period), of the important February 22, 2022 lead plaintiff deadline in the securities class action commenced by the Firm.

RADNOR, Pa.--(BUSINESS WIRE)---- $DOCU--Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against DocuSign, Inc.

Volatility can create prime opportunities to buy companies on sale, but there's more that long-term investors need to consider.

NEW YORK, Feb. 8, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Docusign, Inc. (NASDAQ: DOCU) alleging that the Company violated federal securities laws. Class Period: March 27, 2020 to December 2, 2021 Lead…